学科分类
/ 1
4 个结果
  • 简介:<正>DearSir,IamDr.Zhong-ShanChenfromtheDepartmentofOphthalmology,WuhanGeneralHospitalofGuangzhouMilitaryCommand,HubeiProvince,China.Iwritetopresenttwocaseswithserpiginouschoroiditis(SC)whichisarare,usuallybilateral,chronic,progressiveinflammationofthechoroid,choriocapillarisandretinalpigmentepithelium.InthispaperwepresentedthedifferentoutcomesofSCpatientswithorwithoutsystemicandoculartreatmentsafterlong-termfollow-up.

  • 标签:
  • 简介:AIM:Toevaluatetheeffectsandsafetyofphacoemu-lsification(Phaco)orsmall-incisionextracapsularcataractsurgery(SICS)andintraocularlens(IOL)implantationforagedpatients.METHODS:Totally137agedpatients(149eyes)underwentcataractoperationinthecaseofstablesystemiccondition,thebloodpressurelessthan160/95mmHg,bloodglucoselessthan8mmol/L,andunderthehelpofelectrocardiogramsurveillancebyanesthesiologistsduringtheoperation.106agedpatients(114eyes)underwentPhacowhile31agedpatients(35eyes)underwentSICS.Thepostoperativevisualacuity,cornealendothelialcellloss,surgerytimeandmajorcomplicationswereobservedandanalyzedretrospectively.RESULTS:Thebest-correctedvisualacuity(BCVA)of≥0.6wasachievedin135eyes(92.6%)at1monthpostoperatively(χ2=259.730,P<0.001).Foragedpatients,bothPhacoandSICScouldsignificantlyimprovevisualacuitywithnosignificantdifference(χ2=4.535,P>0.05).Postoperativecornealendothelialcelllosswas18.6%,inPHACOgroup,theratewas18.5%;inSICSgroup,theratewas19.0%,thedifferenceofwhichwasnosignificant(χ2=0.102,P>0.05).Thesurgerytimewasdifferentintwogroups.Noseverecomplicationsoccurred.CONCLUSION:BothPhacoandSICScombinedwithIOLimplantationforagedpatientsareeffectiveandsafe.Beforesurgery,detailedphysicalexaminationshouldbeperformed.Whenthesystemicconditionisstable,cataractsurgeryforagedpatientsissafe.

  • 标签: PHACOEMULSIFICATION small-incision EXTRACAPSULAR CATARACT surgery intraocular
  • 简介:目的探讨中、晚期新生血管性青光眼的治疗方法及疗效。方法对中、晚期新生血管性青光眼29例(30眼),根据屈光间质情况分成光凝组和冷凝组,分别行超全视网膜光凝全视网膜冷凝治疗,再结合行巩膜池小梁切除术,术后观察两组患者的视力、眼压、虹膜新生血管消退情况及并发症等。结果术后随访6-18个月,平均(10.2±3.65)月。术后所有患者眼痛、头痛症状消失。光凝组16例,17眼,术后14眼眼压控制在21mmHg(1mmHg=0.133kPa)以下,手术成功率82.4%,3眼需加用药物控制后眼压〈25mmHg,术后视力提高8眼(47.1%),15眼虹膜新生血管消退,2眼部分消退,残存数根干瘪的新生血管,冷凝组:13眼,术后10眼眼压控制在正常范围,手术成功率为76.7%,2眼需加用药物治疗,1例出现眼球萎缩。术后视力提高3眼(23.1%),11例虹膜新生血管完全消退,2例部分消退。结论超全视网膜光凝冷凝结合巩膜池小梁切除术是治疗中、晚期新生血管性青光眼的有效方法,适于基层医院开展。

  • 标签: 新生血管性青光眼 超全视网膜光凝 视网膜冷凝 巩膜池小梁切除术
  • 简介:AIM:ToinvestigatetheroleofRho-associatedproteinkinase(ROCK)inhibitor,Y27632,inmediatingtheproductionofextracellularmatrix(ECM)componentsincludingfibronectin,matrixmetallo-proteinase-2(MMP-2)andtypeIcollagenasinducedbyconnectivetissuegrowthfactor(CTGF)ortransforminggrowthfactor-β(TGF-β)inahumanretinalpigmentepithelialcellline,ARPE-19.METHODS:TheeffectofY27632ontheCTGForTGF-βinducedphenotypeinARPE-19cellswasmeasuredwithimmunocytochemistryasthechangeinF-actin.ARPE-19cellsweretreatedwithCTGF(1,10,100ng/mL)andTGF-β(10ng/mL)inserumfreemedia,andanalyzedforfibronectin,laminin,andMMP-2andtypeIcollagenbyRT-qPCRandimmunocytochemistry.CellswerealsopretreatedwithanROCKinhibitor,Y27632,toanalyzethesignalingcontributingtoECMproduction.·RESULTS:TreatmentofARPE-19cellsinculturewithTGF-βorCTGFinducedanECMchangefromacobblestonemorphologytoamoreelongatedswirlpatternindicatingamesenchymalphenotype.RT-qPCRanalysisanddifferentgeneexpressionanalysisdemonstratedanupregulationinexpressionofgenesassociatedwithcytoskeletalstructureandmotility.CTGForTGF-βsignificantlyincreasedexpressionoffibronectinmRNA(P=0.006,P=0.003respectively),lamininmRNA(P=0.006,P=0.005),MMP-2mRNA(P=0.006,P=0.001),COL1A1mRNA(P=0.001,P=0.001),COL1A2mRNA(P=0.001,P=0.001).PreincubationofARPE-19withY27632(10mmol/L)significantlypreventedCTGForTGF-βinducedfibronectin(P=0.005,P=0.003respectively),MMP-2(P=0.003,P=0.002),COL1A1(P=0.006,P=0.003),andCOL1A2(P=0.006,P=0.004)geneexpression,butnotlaminin(P=0.375,P=0.516).CONCLUSION:OurstudydemonstratedthatbothTGF-βandCTGFupregulatetheexpressionofECMcomponentsincludingfibronectin,laminin,MMP-2andtypeIcollagenbyactivatingtheRhoA/ROCKsignalingpathway.Duringthisprocess,ARPE-19cellswereshowntochangefromanepithelialtoamesenchymalphenotypeinvi

  • 标签: rho-associated protein kinase inhibitor CONNECTIVE tissue